LFG
KROS icon

Larson Financial Group’s Keros Therapeutics KROS Stock Holding History

Larson Financial Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54 Buy
+5
New +$56 ﹤0.01% 3682
2026
Q1 		– Sell
-245
Closed -$4.99K – 3726
2025
Q4 		$4.99K Sell
245
-49
-17% -$860 ﹤0.01% 2462
2025
Q3 		$4.65K Buy
+294
New +$4.34K ﹤0.01% 2380

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Larson Financial Group's KROS Position: Q2 2026 in Review

Larson Financial Group opened a new position in Keros Therapeutics (KROS) in Q2 2026: 5 shares worth $54. The stake represents ﹤0.01% of the portfolio and ranks #3682 among its holdings. This is a return to the name: Larson Financial Group previously reported a position in KROS as recently as Q4 2025.

Larson Financial Group first reported a position in KROS in Q3 2025 and has held it in 3 quarters since. The position peaked at $4.99K in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Larson Financial Group held 5 shares of Keros Therapeutics worth $54 as of Q2 2026.
  • Keros Therapeutics was a new Larson Financial Group position in Q2 2026.
  • Keros Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3682 holding.
  • Larson Financial Group first reported a position in Keros Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Larson Financial Group's Keros Therapeutics position peaked at $4.99K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.